Silence Historical Balance Sheet

SLN Stock

USD 6.60 0.15 2.33%

Trend analysis of Silence Therapeutics PLC balance sheet accounts such as Property Plant And Equipment Net of 1.9 M, Accounts Payable of 1.7 M, Cash of 56.7 M or Non Current Assets Total of 8.2 M provides information on Silence Therapeutics' total assets, liabilities, and equity, which is the actual value of Silence Therapeutics PLC to its prevalent stockholders. By breaking down trends over time using Silence Therapeutics balance sheet statements, investors will see what precisely the company owns and what it owes to creditors or other parties at the end of each accounting year.

Cash Flow Balance Sheet Income Statement

Covid

Financial Statement Analysis is much more than just reviewing and examining Silence Therapeutics PLC latest accounting reports to predict its past. Macroaxis encourages investors to analyze financial statements over time for various trends across multiple indicators and accounts to determine whether Silence Therapeutics PLC is a good buy for the upcoming year.

Silence Therapeutics Inventory

(17.67 Million)

Check out World Market Map to better understand how to build diversified portfolios, which includes a position in Silence Therapeutics PLC. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in bureau of economic analysis.

About Silence Balance Sheet Analysis

Balance Sheet is a snapshot of the financial position of Silence Therapeutics PLC at a specified time, usually calculated after every quarter, six months, or one year. Silence Therapeutics Balance Sheet has two main parts: assets and liabilities. Liabilities are the debts or obligations of Silence Therapeutics and are divided into current liabilities and long term liabilities. An asset, on the other hand, is anything of value that can be converted into cash and which Silence currently owns. An asset can also be divided into two categories, current and non-current.

Silence Therapeutics Balance Sheet Chart

At this time, Silence Therapeutics' Non Currrent Assets Other are very stable compared to the past year. As of the 13th of December 2024, Cash And Short Term Investments is likely to grow to about 56.7 M, though Net Debt is likely to grow to (51.1 M).

Total Assets Other Current Liab Total Current Liabilities Total Stockholder Equity

Total Assets

Total assets refers to the total amount of Silence Therapeutics assets owned. Assets are items that have some economic value and are expended over time to create a benefit for the owner. These assets are usually recorded in Silence Therapeutics PLC books under different categories such as cash, marketable securities, accounts receivable,prepaid expenses, inventory, fixed assets, intangible assets, other assets, marketable securities, accounts receivable, prepaid expenses and others. The total value of all owned resources that are expected to provide future economic benefits to the business, including cash, investments, accounts receivable, inventory, property, plant, equipment, and intangible assets.

Total Current Liabilities

Total Current Liabilities is an item on Silence Therapeutics balance sheet that include short term debt, accounts payable, accrued salaries payable, payroll taxes payable, accrued liabilities and other debts. Total Current Liabilities of Silence Therapeutics PLC are important to investors because some useful performance ratios such as Current Ratio and Quick Ratio require Total Current Liabilities to be accurate. The total amount of liabilities that a company is expected to pay within one year, including debts, accounts payable, and other short-term financial obligations.

Total Stockholder Equity

The total equity held by shareholders, calculated as the difference between a company's total assets and total liabilities. It represents the net value of the company owned by shareholders.

Most accounts from Silence Therapeutics' balance sheet are interrelated and interconnected. However, analyzing balance sheet accounts one by one will only give a small insight into Silence Therapeutics PLC current financial condition. On the other hand, looking into the entire matrix of balance sheet accounts, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out World Market Map to better understand how to build diversified portfolios, which includes a position in Silence Therapeutics PLC. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in bureau of economic analysis.

	2021	2022	2023	2024 (projected)
Other Current Liabilities	6.2M	589K	14.0M	14.7M
Total Assets	96.2M	107.5M	93.8M	98.5M

Other Current Liab Total Assets

Silence Therapeutics balance sheet Correlations

	Total Assets	Other Current Liab	Total Current Liabilities	Total Stockholder Equity	Property Plant And Equipment Net	Net Debt	Retained Earnings	Accounts Payable	Cash	Non Current Assets Total	Non Currrent Assets Other	Cash And Short Term Investments	Common Stock Total Equity	Common Stock Shares Outstanding	Non Current Liabilities Total	Other Current Assets	Other Stockholder Equity	Total Liab	Property Plant And Equipment Gross	Total Current Assets	Common Stock	Net Receivables	Good Will	Inventory	Intangible Assets	Current Deferred Revenue
Total Assets		0.6	0.86	-0.07	0.95	-0.86	-0.92	0.32	0.87	0.12	-0.35	0.92	0.68	0.89	0.89	0.68	0.86	0.89	0.88	0.98	0.79	0.81	-0.14	-0.66	-0.4	0.69
Other Current Liab	0.6		0.79	-0.4	0.43	-0.3	-0.63	0.15	0.33	-0.02	-0.1	0.35	0.45	0.6	0.67	0.72	0.48	0.7	0.44	0.6	0.49	0.88	-0.13	-0.32	-0.24	0.78
Total Current Liabilities	0.86	0.79		-0.48	0.72	-0.54	-0.85	0.35	0.55	-0.01	-0.32	0.67	0.52	0.75	0.93	0.68	0.65	0.96	0.73	0.86	0.63	0.95	-0.16	-0.55	-0.23	0.87
Total Stockholder Equity	-0.07	-0.4	-0.48		0.05	-0.16	0.21	-0.1	0.15	0.25	0.18	0.09	0.17	0.03	-0.51	-0.26	0.16	-0.51	-0.25	-0.11	0.06	-0.39	0.08	0.07	-0.35	-0.29
Property Plant And Equipment Net	0.95	0.43	0.72	0.05		-0.92	-0.88	0.3	0.93	0.04	-0.31	0.95	0.58	0.9	0.81	0.64	0.87	0.8	0.9	0.95	0.7	0.67	-0.25	-0.7	-0.43	0.54
Net Debt	-0.86	-0.3	-0.54	-0.16	-0.92		0.75	-0.21	-1.0	0.04	0.34	-0.96	-0.46	-0.8	-0.7	-0.51	-0.78	-0.67	-0.83	-0.88	-0.56	-0.48	0.32	0.54	0.51	-0.37
Retained Earnings	-0.92	-0.63	-0.85	0.21	-0.88	0.75		-0.4	-0.77	-0.04	0.12	-0.83	-0.63	-0.93	-0.89	-0.81	-0.92	-0.89	-0.91	-0.91	-0.78	-0.78	0.23	0.79	0.37	-0.57
Accounts Payable	0.32	0.15	0.35	-0.1	0.3	-0.21	-0.4		0.2	0.0	0.46	0.39	0.36	0.49	0.3	-0.02	0.44	0.31	0.22	0.33	0.32	0.12	-0.14	0.02	-0.51	0.17
Cash	0.87	0.33	0.55	0.15	0.93	-1.0	-0.77	0.2		-0.04	-0.33	0.96	0.47	0.81	0.71	0.54	0.8	0.68	0.85	0.89	0.58	0.5	-0.32	-0.57	-0.49	0.37
Non Current Assets Total	0.12	-0.02	-0.01	0.25	0.04	0.04	-0.04	0.0	-0.04		-0.14	-0.07	0.72	-0.07	-0.01	-0.01	0.1	-0.01	0.02	-0.06	0.61	-0.01	0.9	-0.05	0.31	-0.02
Non Currrent Assets Other	-0.35	-0.1	-0.32	0.18	-0.31	0.34	0.12	0.46	-0.33	-0.14		-0.26	-0.06	0.01	-0.39	-0.04	0.05	-0.38	-0.3	-0.33	-0.11	-0.36	-0.13	0.09	-0.15	-0.43
Cash And Short Term Investments	0.92	0.35	0.67	0.09	0.95	-0.96	-0.83	0.39	0.96	-0.07	-0.26		0.5	0.88	0.76	0.5	0.84	0.75	0.84	0.94	0.61	0.57	-0.36	-0.56	-0.57	0.48
Common Stock Total Equity	0.68	0.45	0.52	0.17	0.58	-0.46	-0.63	0.36	0.47	0.72	-0.06	0.5		0.59	0.51	0.47	0.68	0.51	0.52	0.55	0.96	0.48	0.51	-0.42	-0.15	0.38
Common Stock Shares Outstanding	0.89	0.6	0.75	0.03	0.9	-0.8	-0.93	0.49	0.81	-0.07	0.01	0.88	0.59		0.75	0.71	0.96	0.76	0.8	0.91	0.69	0.7	-0.38	-0.66	-0.63	0.56
Non Current Liabilities Total	0.89	0.67	0.93	-0.51	0.81	-0.7	-0.89	0.3	0.71	-0.01	-0.39	0.76	0.51	0.75		0.71	0.67	1.0	0.9	0.89	0.65	0.83	-0.16	-0.61	-0.17	0.67
Other Current Assets	0.68	0.72	0.68	-0.26	0.64	-0.51	-0.81	-0.02	0.54	-0.01	-0.04	0.5	0.47	0.71	0.71		0.7	0.72	0.77	0.67	0.64	0.75	-0.14	-0.85	-0.02	0.43
Other Stockholder Equity	0.86	0.48	0.65	0.16	0.87	-0.78	-0.92	0.44	0.8	0.1	0.05	0.84	0.68	0.96	0.67	0.7		0.67	0.79	0.84	0.78	0.6	-0.24	-0.73	-0.55	0.42
Total Liab	0.89	0.7	0.96	-0.51	0.8	-0.67	-0.89	0.31	0.68	-0.01	-0.38	0.75	0.51	0.76	1.0	0.72	0.67		0.87	0.9	0.66	0.87	-0.16	-0.61	-0.18	0.72
Property Plant And Equipment Gross	0.88	0.44	0.73	-0.25	0.9	-0.83	-0.91	0.22	0.85	0.02	-0.3	0.84	0.52	0.8	0.9	0.77	0.79	0.87		0.87	0.7	0.65	-0.18	-0.81	-0.16	0.39
Total Current Assets	0.98	0.6	0.86	-0.11	0.95	-0.88	-0.91	0.33	0.89	-0.06	-0.33	0.94	0.55	0.91	0.89	0.67	0.84	0.9	0.87		0.67	0.81	-0.32	-0.64	-0.47	0.71
Common Stock	0.79	0.49	0.63	0.06	0.7	-0.56	-0.78	0.32	0.58	0.61	-0.11	0.61	0.96	0.69	0.65	0.64	0.78	0.66	0.7	0.67		0.59	0.39	-0.64	-0.1	0.42
Net Receivables	0.81	0.88	0.95	-0.39	0.67	-0.48	-0.78	0.12	0.5	-0.01	-0.36	0.57	0.48	0.7	0.83	0.75	0.6	0.87	0.65	0.81	0.59		-0.15	-0.56	-0.2	0.91
Good Will	-0.14	-0.13	-0.16	0.08	-0.25	0.32	0.23	-0.14	-0.32	0.9	-0.13	-0.36	0.51	-0.38	-0.16	-0.14	-0.24	-0.16	-0.18	-0.32	0.39	-0.15		0.12	0.59	-0.16
Inventory	-0.66	-0.32	-0.55	0.07	-0.7	0.54	0.79	0.02	-0.57	-0.05	0.09	-0.56	-0.42	-0.66	-0.61	-0.85	-0.73	-0.61	-0.81	-0.64	-0.64	-0.56	0.12		-0.05	-0.25
Intangible Assets	-0.4	-0.24	-0.23	-0.35	-0.43	0.51	0.37	-0.51	-0.49	0.31	-0.15	-0.57	-0.15	-0.63	-0.17	-0.02	-0.55	-0.18	-0.16	-0.47	-0.1	-0.2	0.59	-0.05		-0.31
Current Deferred Revenue	0.69	0.78	0.87	-0.29	0.54	-0.37	-0.57	0.17	0.37	-0.02	-0.43	0.48	0.38	0.56	0.67	0.43	0.42	0.72	0.39	0.71	0.42	0.91	-0.16	-0.25	-0.31

Click cells to compare fundamentals

Silence Therapeutics Account Relationship Matchups

Silence Therapeutics balance sheet Accounts

	2019	2020	2021	2022	2023	2024 (projected)
Total Assets	46.1M	86.0M	96.2M	107.5M	93.8M	98.5M
Other Current Liab	5.1M	21.8M	6.2M	589K	14.0M	14.7M
Total Current Liabilities	9.7M	25.6M	15.2M	21.9M	17.8M	18.7M
Total Stockholder Equity	20.9M	9.1M	8.5M	22.1M	17.1M	20.8M
Property Plant And Equipment Net	611K	1.1M	1.9M	2.2M	1.8M	1.9M
Net Debt	(13.2M)	(27.1M)	(73.4M)	(54.4M)	(53.8M)	(51.1M)
Retained Earnings	(152.0M)	(184.2M)	(223.0M)	(263.3M)	(304.6M)	(289.4M)
Accounts Payable	6.9M	2.3M	4.1M	3.2M	2.6M	1.7M
Cash	13.5M	27.4M	73.5M	54.8M	54.0M	56.7M
Non Current Assets Total	8.6M	9.6M	9.9M	10.8M	12.8M	8.2M
Non Currrent Assets Other	20.0M	(9.6M)	(9.9M)	(10.8M)	2.6M	2.7M
Cash And Short Term Investments	33.5M	37.4M	73.5M	71.1M	54.0M	56.7M
Common Stock Total Equity	3.5M	3.6M	3.9M	4.2M	4.8M	5.0M
Common Stock Shares Outstanding	25.0M	27.3M	29.7M	32.2M	37.1M	38.9M
Liabilities And Stockholders Equity	46.1M	86.0M	96.2M	107.5M	93.8M	98.5M
Non Current Liabilities Total	15.5M	51.3M	72.5M	63.5M	59.0M	62.0M
Other Current Assets	885K	9.6M	4.3M	8.2M	26.8M	28.1M
Other Stockholder Equity	171.9M	153.7M	184.3M	226.7M	251.4M	264.0M
Total Liab	25.2M	76.9M	87.7M	85.4M	76.8M	80.6M
Property Plant And Equipment Gross	611K	1.1M	5.5M	5.5M	5.6M	5.8M
Total Current Assets	37.5M	76.4M	86.3M	96.7M	81.0M	85.1M
Common Stock	3.9M	4.2M	4.5M	5.4M	5.9M	6.2M
Accumulated Other Comprehensive Income	169.0M	189.1M	23.8M	24.3M	64.3M	57.1M
Net Receivables	3.1M	29.3M	8.5M	17.3M	18.8M	19.8M
Good Will	7.7M	8.1M	7.6M	8.0M	7.8M	7.8M
Intangible Assets	34K	17K	24K	320K	284K	313.7K
Short Term Investments	319K	5.0M	20.0M	10M	0.0	16.3M
Net Tangible Assets	13.2M	917K	910K	13.7M	12.4M	16.7M
Property Plant Equipment	611K	1.1M	1.9M	2.2M	2.5M	1.5M
Net Invested Capital	20.9M	9.1M	8.5M	22.1M	17.1M	18.9M
Net Working Capital	27.8M	50.8M	71.2M	74.7M	63.3M	56.0M
Capital Stock	3.9M	4.2M	4.5M	5.4M	5.9M	5.0M

Pair Trading with Silence Therapeutics

One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Silence Therapeutics position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Silence Therapeutics will appreciate offsetting losses from the drop in the long position's value.

Moving together with Silence Stock

0.9	VALN	Valneva SE ADR	Pair Corr
0.89	ERNA	Eterna Therapeutics	Pair Corr

Moving against Silence Stock

0.84	DYAI	Dyadic International	Pair Corr
0.78	ESPR	Esperion Therapeutics	Pair Corr
0.77	BMY	Bristol Myers Squibb	Pair Corr
0.57	GILD	Gilead Sciences	Pair Corr
0.37	DNA	Ginkgo Bioworks Holdings	Pair Corr

The ability to find closely correlated positions to Silence Therapeutics could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Silence Therapeutics when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Silence Therapeutics - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Silence Therapeutics PLC to buy it.

The correlation of Silence Therapeutics is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Silence Therapeutics moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Silence Therapeutics PLC moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.

Correlation analysis and pair trading evaluation for Silence Therapeutics can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.

Pair Correlation Correlation Matching

When determining whether Silence Therapeutics PLC offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Silence Therapeutics' financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Silence Therapeutics Plc Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Silence Therapeutics Plc Stock:

How To Invest In Silence

Details

Is Silence Stock a good investment?

Details

What is Silence Therapeutics' Net Worth?

Details

Largest Biotechnology Companies

View

Largest Pharmaceuticals, Biotechnology & Life Sciences Companies

View

You can also try the Stock Screener module to find equities using a custom stock filter or screen asymmetry in trading patterns, price, volume, or investment outlook..

Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Silence Therapeutics. If investors know Silence will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Silence Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.

Earnings Share

(1.76)

Revenue Per Share

0.429

Quarterly Revenue Growth

(0.93)

Return On Assets

(0.22)

Return On Equity

(0.64)

The market value of Silence Therapeutics PLC is measured differently than its book value, which is the value of Silence that is recorded on the company's balance sheet. Investors also form their own opinion of Silence Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Silence Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Silence Therapeutics' market value can be influenced by many factors that don't directly affect Silence Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.

Please note, there is a significant difference between Silence Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Silence Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Silence Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC

Silence Historical Balance Sheet

Silence Therapeutics Inventory

(17.67 Million)

About Silence Balance Sheet Analysis

Silence Therapeutics Balance Sheet Chart

Total Assets

Total Current Liabilities

Total Stockholder Equity

Silence Therapeutics balance sheet Correlations

Silence Therapeutics Account Relationship Matchups

High Positive Relationship

High Negative Relationship

Silence Therapeutics balance sheet Accounts

Pair Trading with Silence Therapeutics

Moving together with Silence Stock

Moving against Silence Stock

COMMON DESTINATIONS

MAIN CATEGORIES

COMPANY

Total Liab	+ 1.0	Non Current Liabilities Total
Total Current Assets	+ 0.98	Total Assets
Total Liab	+ 0.96	Total Current Liabilities
Cash And Short Term Investments	+ 0.96	Cash
Common Stock	+ 0.96	Common Stock Total Equity
Other Stockholder Equity	+ 0.96	Common Stock Shares Outstanding

Cash	- 1.0	Net Debt
Cash And Short Term Investments	- 0.96	Net Debt
Common Stock Shares Outstanding	- 0.93	Retained Earnings
Other Stockholder Equity	- 0.92	Retained Earnings
Net Debt	- 0.92	Property Plant And Equipment Net
Retained Earnings	- 0.92	Total Assets